Cell surface antigen targeted agents, in particular PSMA targeted urea-based ligands and antibodies, have now been assessed in a wide range of scenarios to detect and treat metastatic prostate cancer. This evidence concerns the gene FOLH1 and metastatic prostate carcinoma.